Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegbelfermin in NASH with Compensated Cirrhosis
NCT03486912Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
A Phase 2 trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH), Liver cirrhosis (LC), sponsored by Bristol Myers Squibb. Started Jun 2018; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03486912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486912.